July 13, 2011
Wisconsin can and should properly leverage the substantial economic advantages it has with this dynamic industry. The study finds credible evidence of the growing impact of bioscience throughout the state in the health, energy and agriculture sectors.
July 11, 2011
By John Horton, President of LegitScript
Oregon Statesman Journal
In just the first three days of summer, at least six unrelated pharmaceutical manufacturers you’ve probably never heard of — companies with names like Xcellerex, Avesthagen, NeuClone and Lupin — were the subject of various press releases. The content varied, but all of the news involved the companies’ plans to refocus their business strategies on a promising new area of medicine: biologics. Read more.
July 11, 2011
By John Horton, President of LegitScript
Oregon Statesman Journal
In just the first three days of summer, at least six unrelated pharmaceutical manufacturers you’ve probably never heard of — companies with names like Xcellerex, Avesthagen, NeuClone and Lupin — were the subject of various press releases. The content varied, but all of the news involved the companies’ plans to refocus their business strategies on a promising new area of medicine: biologics. Read more.
June 29, 2011
By Andrew R. Spiegel
CEO, Colon Cancer Alliance
MedCity News
Prevention is a key message of the Colon Cancer Alliance. Over 80% of all cases of colorectal cancer can be prevented with recommended screenings. Despite its high incidence, colorectal cancer is one of the most detectable and, if found early enough, most treatable forms of cancer. With the widespread adoption of common screening practices, as many as 30,000 lives could be saved each year. Read More.
June 24, 2011
By Bruce S. Rubin, MD
Assistant Professor of Clinical Neurology, University of Miami Miller School of Medicine
Opposing Views
Scientific advancements in medicine are important achievements that improve quality of life for many people. One recent example is in the field of biotech medicines. But in the rush to make generic versions of these drugs, patient safety could be compromised. Read More
June 23, 2011
Less expensive, follow-on biologics are expected to be a boon to patients and Washington’s biotechnology industry. But as the FDA implements a new approval pathway for these complicated drugs, the medical community wants to ensure patient safety comes first.
June 23, 2011
The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on biosimilar medicines. Clusters are topic areas of mutual interest for the two agencies, which they have identified as benefiting from the regular exchange of information and collaborative meetings. Biosimilar medicines is the latest addition to the existing list of topics, which already includes medicines to treat cancer, orphan medicines, medicines for children and blood-based products. Read more.
June 21, 2011
November 18, 2011
Seattle, WA
Read More
June 21, 2011
September 20, 2011
Institute for Stem Cell & Regenerative Medicine
Seattle, WA
Read More
